Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society
Type 2 diabetes mellitus is characterized by an increased risk of developing long-term cardiovascular complications. Several underlying mechanisms have been proposed for the diabetes-related increase in cardiovascular risk, i.e. chronic hyperglycemia, duration of the disease, drug-induced hypoglycem...
Gespeichert in:
| Veröffentlicht in: | Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2020-10, Vol.30 (11), p.1926-1936 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1936 |
|---|---|
| container_issue | 11 |
| container_start_page | 1926 |
| container_title | Nutrition, metabolism, and cardiovascular diseases |
| container_volume | 30 |
| creator | Napoli, Raffaele Formoso, Gloria Piro, Salvatore Targher, Giovanni Consoli, Agostino Purrello, Francesco |
| description | Type 2 diabetes mellitus is characterized by an increased risk of developing long-term cardiovascular complications. Several underlying mechanisms have been proposed for the diabetes-related increase in cardiovascular risk, i.e. chronic hyperglycemia, duration of the disease, drug-induced hypoglycemia, coexistence of multiple cardiovascular risk factors, etc. In the last few years, new pharmacological approaches capable of treating chronic hyperglycemia without increasing the risk of hypoglycemia have emerged for the treatment of diabetes.
With data mainly obtained from randomized controlled trials recruiting patients with type 2 diabetes in secondary prevention of cardiovascular disease, some of these newer antihyperglycemic drugs have shown to significantly reduce the risk of cardiovascular disease. In addition, the combined control of traditional cardiovascular risk factors, e.g. dyslipidemia, hypertension, etc., has demonstrated to be effective in reducing the burden of cardiovascular diseases in patients with type 2 diabetes.
In this document written by some experts of the Italian diabetes society (SID), we will focus our attention on oral antihyperglycemic agents for people with type 2 diabetes in primary or secondary prevention of cardiovascular disease, excluding for brevity the injection therapies for diabetes, such as insulin and glucagon-like peptide-1 receptor agonists. |
| doi_str_mv | 10.1016/j.numecd.2020.07.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2442847531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939475320302878</els_id><sourcerecordid>2442847531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-ba31d6e2cb1f434394a62562aac7816caadec8fb06d5d28eb7c2a610864199a33</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi1ERZfCP0DIRy4J_lonuSBVbYFKrTgAZ2tiT8CrxA52sur-e7zaLUdOc5jnfUfzEPKOs5ozrj_u6rBOaF0tmGA1a2rGxQuy4duOVbIR3UuyYZ3sKtVs5SV5nfOOMdkwqV6RSyk60WrRbsjhEQL8wgnDQuNAl8OMVFDnoccFMx1ionPCfVn7GI6EheR83EO26wipkBkhY02vA8WnGVOpmX04w8tvpPcLjB4CvX3u_B6tx-XwhlwMMGZ8e55X5Ofnux83X6uHb1_ub64fKiu1WKoeJHcahe35oKSSnQIttloA2Kbl2gI4tO3QM-22TrTYN1aA5qzVincdSHlFPpx65xT_rJgXM_lscRwhYFyzEUqJ9iiJF1SdUJtizgkHMyc_QToYzsxRutmZk3RzlG5YY4r0Ent_vrD2E7p_oWfLBfh0ArD8ufeYTC4KgkXnE9rFuOj_f-EvPmaWMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2442847531</pqid></control><display><type>article</type><title>Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Napoli, Raffaele ; Formoso, Gloria ; Piro, Salvatore ; Targher, Giovanni ; Consoli, Agostino ; Purrello, Francesco</creator><creatorcontrib>Napoli, Raffaele ; Formoso, Gloria ; Piro, Salvatore ; Targher, Giovanni ; Consoli, Agostino ; Purrello, Francesco</creatorcontrib><description>Type 2 diabetes mellitus is characterized by an increased risk of developing long-term cardiovascular complications. Several underlying mechanisms have been proposed for the diabetes-related increase in cardiovascular risk, i.e. chronic hyperglycemia, duration of the disease, drug-induced hypoglycemia, coexistence of multiple cardiovascular risk factors, etc. In the last few years, new pharmacological approaches capable of treating chronic hyperglycemia without increasing the risk of hypoglycemia have emerged for the treatment of diabetes.
With data mainly obtained from randomized controlled trials recruiting patients with type 2 diabetes in secondary prevention of cardiovascular disease, some of these newer antihyperglycemic drugs have shown to significantly reduce the risk of cardiovascular disease. In addition, the combined control of traditional cardiovascular risk factors, e.g. dyslipidemia, hypertension, etc., has demonstrated to be effective in reducing the burden of cardiovascular diseases in patients with type 2 diabetes.
In this document written by some experts of the Italian diabetes society (SID), we will focus our attention on oral antihyperglycemic agents for people with type 2 diabetes in primary or secondary prevention of cardiovascular disease, excluding for brevity the injection therapies for diabetes, such as insulin and glucagon-like peptide-1 receptor agonists.</description><identifier>ISSN: 0939-4753</identifier><identifier>EISSN: 1590-3729</identifier><identifier>DOI: 10.1016/j.numecd.2020.07.012</identifier><identifier>PMID: 32928628</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Oral ; Biomarkers - blood ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; Cardiovascular diseases ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - prevention & control ; CVD prevention ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - epidemiology ; Glycemic Control ; Heart Disease Risk Factors ; Humans ; Hypoglycemic Agents - administration & dosage ; Primary Prevention ; Protective Factors ; Risk Assessment ; Secondary Prevention ; Treatment Outcome</subject><ispartof>Nutrition, metabolism, and cardiovascular diseases, 2020-10, Vol.30 (11), p.1926-1936</ispartof><rights>2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University</rights><rights>Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-ba31d6e2cb1f434394a62562aac7816caadec8fb06d5d28eb7c2a610864199a33</citedby><cites>FETCH-LOGICAL-c362t-ba31d6e2cb1f434394a62562aac7816caadec8fb06d5d28eb7c2a610864199a33</cites><orcidid>0000-0002-3366-2321</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.numecd.2020.07.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3538,27906,27907,45977</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32928628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Napoli, Raffaele</creatorcontrib><creatorcontrib>Formoso, Gloria</creatorcontrib><creatorcontrib>Piro, Salvatore</creatorcontrib><creatorcontrib>Targher, Giovanni</creatorcontrib><creatorcontrib>Consoli, Agostino</creatorcontrib><creatorcontrib>Purrello, Francesco</creatorcontrib><title>Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society</title><title>Nutrition, metabolism, and cardiovascular diseases</title><addtitle>Nutr Metab Cardiovasc Dis</addtitle><description>Type 2 diabetes mellitus is characterized by an increased risk of developing long-term cardiovascular complications. Several underlying mechanisms have been proposed for the diabetes-related increase in cardiovascular risk, i.e. chronic hyperglycemia, duration of the disease, drug-induced hypoglycemia, coexistence of multiple cardiovascular risk factors, etc. In the last few years, new pharmacological approaches capable of treating chronic hyperglycemia without increasing the risk of hypoglycemia have emerged for the treatment of diabetes.
With data mainly obtained from randomized controlled trials recruiting patients with type 2 diabetes in secondary prevention of cardiovascular disease, some of these newer antihyperglycemic drugs have shown to significantly reduce the risk of cardiovascular disease. In addition, the combined control of traditional cardiovascular risk factors, e.g. dyslipidemia, hypertension, etc., has demonstrated to be effective in reducing the burden of cardiovascular diseases in patients with type 2 diabetes.
In this document written by some experts of the Italian diabetes society (SID), we will focus our attention on oral antihyperglycemic agents for people with type 2 diabetes in primary or secondary prevention of cardiovascular disease, excluding for brevity the injection therapies for diabetes, such as insulin and glucagon-like peptide-1 receptor agonists.</description><subject>Administration, Oral</subject><subject>Biomarkers - blood</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>CVD prevention</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Glycemic Control</subject><subject>Heart Disease Risk Factors</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Primary Prevention</subject><subject>Protective Factors</subject><subject>Risk Assessment</subject><subject>Secondary Prevention</subject><subject>Treatment Outcome</subject><issn>0939-4753</issn><issn>1590-3729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi1ERZfCP0DIRy4J_lonuSBVbYFKrTgAZ2tiT8CrxA52sur-e7zaLUdOc5jnfUfzEPKOs5ozrj_u6rBOaF0tmGA1a2rGxQuy4duOVbIR3UuyYZ3sKtVs5SV5nfOOMdkwqV6RSyk60WrRbsjhEQL8wgnDQuNAl8OMVFDnoccFMx1ionPCfVn7GI6EheR83EO26wipkBkhY02vA8WnGVOpmX04w8tvpPcLjB4CvX3u_B6tx-XwhlwMMGZ8e55X5Ofnux83X6uHb1_ub64fKiu1WKoeJHcahe35oKSSnQIttloA2Kbl2gI4tO3QM-22TrTYN1aA5qzVincdSHlFPpx65xT_rJgXM_lscRwhYFyzEUqJ9iiJF1SdUJtizgkHMyc_QToYzsxRutmZk3RzlG5YY4r0Ent_vrD2E7p_oWfLBfh0ArD8ufeYTC4KgkXnE9rFuOj_f-EvPmaWMQ</recordid><startdate>20201030</startdate><enddate>20201030</enddate><creator>Napoli, Raffaele</creator><creator>Formoso, Gloria</creator><creator>Piro, Salvatore</creator><creator>Targher, Giovanni</creator><creator>Consoli, Agostino</creator><creator>Purrello, Francesco</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3366-2321</orcidid></search><sort><creationdate>20201030</creationdate><title>Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society</title><author>Napoli, Raffaele ; Formoso, Gloria ; Piro, Salvatore ; Targher, Giovanni ; Consoli, Agostino ; Purrello, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-ba31d6e2cb1f434394a62562aac7816caadec8fb06d5d28eb7c2a610864199a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Administration, Oral</topic><topic>Biomarkers - blood</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>CVD prevention</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Glycemic Control</topic><topic>Heart Disease Risk Factors</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Primary Prevention</topic><topic>Protective Factors</topic><topic>Risk Assessment</topic><topic>Secondary Prevention</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Napoli, Raffaele</creatorcontrib><creatorcontrib>Formoso, Gloria</creatorcontrib><creatorcontrib>Piro, Salvatore</creatorcontrib><creatorcontrib>Targher, Giovanni</creatorcontrib><creatorcontrib>Consoli, Agostino</creatorcontrib><creatorcontrib>Purrello, Francesco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Napoli, Raffaele</au><au>Formoso, Gloria</au><au>Piro, Salvatore</au><au>Targher, Giovanni</au><au>Consoli, Agostino</au><au>Purrello, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society</atitle><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle><addtitle>Nutr Metab Cardiovasc Dis</addtitle><date>2020-10-30</date><risdate>2020</risdate><volume>30</volume><issue>11</issue><spage>1926</spage><epage>1936</epage><pages>1926-1936</pages><issn>0939-4753</issn><eissn>1590-3729</eissn><abstract>Type 2 diabetes mellitus is characterized by an increased risk of developing long-term cardiovascular complications. Several underlying mechanisms have been proposed for the diabetes-related increase in cardiovascular risk, i.e. chronic hyperglycemia, duration of the disease, drug-induced hypoglycemia, coexistence of multiple cardiovascular risk factors, etc. In the last few years, new pharmacological approaches capable of treating chronic hyperglycemia without increasing the risk of hypoglycemia have emerged for the treatment of diabetes.
With data mainly obtained from randomized controlled trials recruiting patients with type 2 diabetes in secondary prevention of cardiovascular disease, some of these newer antihyperglycemic drugs have shown to significantly reduce the risk of cardiovascular disease. In addition, the combined control of traditional cardiovascular risk factors, e.g. dyslipidemia, hypertension, etc., has demonstrated to be effective in reducing the burden of cardiovascular diseases in patients with type 2 diabetes.
In this document written by some experts of the Italian diabetes society (SID), we will focus our attention on oral antihyperglycemic agents for people with type 2 diabetes in primary or secondary prevention of cardiovascular disease, excluding for brevity the injection therapies for diabetes, such as insulin and glucagon-like peptide-1 receptor agonists.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32928628</pmid><doi>10.1016/j.numecd.2020.07.012</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-3366-2321</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-4753 |
| ispartof | Nutrition, metabolism, and cardiovascular diseases, 2020-10, Vol.30 (11), p.1926-1936 |
| issn | 0939-4753 1590-3729 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2442847531 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Cardiovascular diseases Cardiovascular Diseases - diagnosis Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control CVD prevention Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Glycemic Control Heart Disease Risk Factors Humans Hypoglycemic Agents - administration & dosage Primary Prevention Protective Factors Risk Assessment Secondary Prevention Treatment Outcome |
| title | Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A24%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20type%202%20diabetes%20for%20prevention%20of%20cardiovascular%20disease.%20An%20expert%20opinion%20of%20the%20Italian%20Diabetes%20Society&rft.jtitle=Nutrition,%20metabolism,%20and%20cardiovascular%20diseases&rft.au=Napoli,%20Raffaele&rft.date=2020-10-30&rft.volume=30&rft.issue=11&rft.spage=1926&rft.epage=1936&rft.pages=1926-1936&rft.issn=0939-4753&rft.eissn=1590-3729&rft_id=info:doi/10.1016/j.numecd.2020.07.012&rft_dat=%3Cproquest_cross%3E2442847531%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2442847531&rft_id=info:pmid/32928628&rft_els_id=S0939475320302878&rfr_iscdi=true |